In a study performed by Elabi et al. on the impact of DPP-4 inhibitors on BBB integrity in T2DM patients, it was observed that the resulting increase in endogenous GLP-1 (glucagon-like protein) may contribute to the protection and maintenance of the BBB. Here, DPP4 is linked to type 2 diabetes mellitus.